ID   M3K5_HUMAN              Reviewed;        1374 AA.
AC   Q99683; A6NIA0; B4DGB2; Q5THN3; Q99461;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   10-MAY-2017, entry version 184.
DE   RecName: Full=Mitogen-activated protein kinase kinase kinase 5;
DE            EC=2.7.11.25;
DE   AltName: Full=Apoptosis signal-regulating kinase 1;
DE            Short=ASK-1;
DE   AltName: Full=MAPK/ERK kinase kinase 5;
DE            Short=MEK kinase 5;
DE            Short=MEKK 5;
GN   Name=MAP3K5; Synonyms=ASK1, MAPKKK5, MEKK5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=8940179; DOI=10.1074/jbc.271.49.31607;
RA   Wang X.S., Diener K., Jannuzzi D., Trollinger D., Tan T.-H.,
RA   Lichenstein H., Zukowski M., Yao Z.;
RT   "Molecular cloning and characterization of a novel protein kinase with
RT   a catalytic domain homologous to mitogen-activated protein kinase
RT   kinase kinase.";
RL   J. Biol. Chem. 271:31607-31611(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=8974401; DOI=10.1126/science.275.5296.90;
RA   Ichijo H., Nishida E., Irie K., ten Dijke P., Saitoh M., Moriguchi T.,
RA   Takagi M., Matsumoto K., Miyazono K., Gotoh Y.;
RT   "Induction of apoptosis by ASK1, a mammalian MAPKKK that activates
RT   SAPK/JNK and p38 signaling pathways.";
RL   Science 275:90-94(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Amygdala;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Eye, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INTERACTION WITH TXN, ENZYME REGULATION, AND FUNCTION.
RX   PubMed=9564042; DOI=10.1093/emboj/17.9.2596;
RA   Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y.,
RA   Kawabata M., Miyazono K., Ichijo H.;
RT   "Mammalian thioredoxin is a direct inhibitor of apoptosis signal-
RT   regulating kinase (ASK) 1.";
RL   EMBO J. 17:2596-2606(1998).
RN   [7]
RP   ENZYME REGULATION, INTERACTION WITH TRAF2, AND FUNCTION.
RX   PubMed=9774977; DOI=10.1016/S1097-2765(00)80283-X;
RA   Nishitoh H., Saitoh M., Mochida Y., Takeda K., Nakano H., Rothe M.,
RA   Miyazono K., Ichijo H.;
RT   "ASK1 is essential for JNK/SAPK activation by TRAF2.";
RL   Mol. Cell 2:389-395(1998).
RN   [8]
RP   INTERACTION WITH DAXX, AND MUTAGENESIS OF LYS-709.
RX   PubMed=9743501; DOI=10.1126/science.281.5384.1860;
RA   Chang H.Y., Nishitoh H., Yang X., Ichijo H., Baltimore D.;
RT   "Activation of apoptosis signal-regulating kinase 1 (ASK1) by the
RT   adapter protein Daxx.";
RL   Science 281:1860-1863(1998).
RN   [9]
RP   INTERACTION WITH 14-3-3 PROTEINS, ENZYME REGULATION, MUTAGENESIS OF
RP   SER-966, AND FUNCTION.
RX   PubMed=10411906; DOI=10.1073/pnas.96.15.8511;
RA   Zhang L., Chen J., Fu H.;
RT   "Suppression of apoptosis signal-regulating kinase 1-induced cell
RT   death by 14-3-3 proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:8511-8515(1999).
RN   [10]
RP   FUNCTION IN APOPTOSIS.
RX   PubMed=10849426; DOI=10.1074/jbc.M003412200;
RA   Hatai T., Matsuzawa A., Inoshita S., Mochida Y., Kuroda T.,
RA   Sakamaki K., Kuida K., Yonehara S., Ichijo H., Takeda K.;
RT   "Execution of apoptosis signal-regulating kinase 1 (ASK1)-induced
RT   apoptosis by the mitochondria-dependent caspase activation.";
RL   J. Biol. Chem. 275:26576-26581(2000).
RN   [11]
RP   SUBUNIT, INTERACTION WITH TRAF2, ENZYME REGULATION, AND FUNCTION.
RX   PubMed=10688666; DOI=10.1128/MCB.20.6.2198-2208.2000;
RA   Liu H., Nishitoh H., Ichijo H., Kyriakis J.M.;
RT   "Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor
RT   necrosis factor receptor-associated factor 2 requires prior
RT   dissociation of the ASK1 inhibitor thioredoxin.";
RL   Mol. Cell. Biol. 20:2198-2208(2000).
RN   [12]
RP   INTERACTION WITH ARRB2.
RX   PubMed=11090355; DOI=10.1126/science.290.5496.1574;
RA   McDonald P.H., Chow C.W., Miller W.E., Laporte S.A., Field M.E.,
RA   Lin F.-T., Davis R.J., Lefkowitz R.J.;
RT   "Beta-arrestin 2: a receptor-regulated MAPK scaffold for the
RT   activation of JNK3.";
RL   Science 290:1574-1577(2000).
RN   [13]
RP   INTERACTION WITH PPP5C, DEPHOSPHORYLATION AT THR-838, SUBCELLULAR
RP   LOCATION, ENZYME REGULATION, AND FUNCTION.
RX   PubMed=11689443; DOI=10.1093/emboj/20.21.6028;
RA   Morita K., Saitoh M., Tobiume K., Matsuura H., Enomoto S.,
RA   Nishitoh H., Ichijo H.;
RT   "Negative feedback regulation of ASK1 by protein phosphatase 5 (PP5)
RT   in response to oxidative stress.";
RL   EMBO J. 20:6028-6036(2001).
RN   [14]
RP   FUNCTION IN KERATINOCYTE DIFFERENTIATION.
RX   PubMed=11029458; DOI=10.1074/jbc.M003425200;
RA   Sayama K., Hanakawa Y., Shirakata Y., Yamasaki K., Sawada Y., Sun L.,
RA   Yamanishi K., Ichijo H., Hashimoto K.;
RT   "Apoptosis signal-regulating kinase 1 (ASK1) is an intracellular
RT   inducer of keratinocyte differentiation.";
RL   J. Biol. Chem. 276:999-1004(2001).
RN   [15]
RP   PHOSPHORYLATION AT SER-83, ENZYME REGULATION, AND FUNCTION.
RX   PubMed=11154276; DOI=10.1128/MCB.21.3.893-901.2001;
RA   Kim A.H., Khursigara G., Sun X., Franke T.F., Chao M.V.;
RT   "Akt phosphorylates and negatively regulates apoptosis signal-
RT   regulating kinase 1.";
RL   Mol. Cell. Biol. 21:893-901(2001).
RN   [16]
RP   INTERACTION WITH HIV-1 NEF, AND INHIBITION BY HIV-1 NEF.
RX   PubMed=11298454; DOI=10.1038/35071111;
RA   Geleziunas R., Xu W., Takeda K., Ichijo H., Greene W.C.;
RT   "HIV-1 Nef inhibits ASK1-dependent death signalling providing a
RT   potential mechanism for protecting the infected host cell.";
RL   Nature 410:834-838(2001).
RN   [17]
RP   INTERACTION WITH RAF1.
RX   PubMed=11427728; DOI=10.1073/pnas.141224398;
RA   Chen J., Fujii K., Zhang L., Roberts T., Fu H.;
RT   "Raf-1 promotes cell survival by antagonizing apoptosis signal-
RT   regulating kinase 1 through a MEK-ERK independent mechanism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:7783-7788(2001).
RN   [18]
RP   INTERACTION WITH TRAF2 AND ERN1, ENZYME REGULATION, AND FUNCTION IN ER
RP   STRESS RESPONSE.
RX   PubMed=14749717; DOI=10.1038/sj.embor.7400072;
RA   Takeda K., Matsuzawa A., Nishitoh H., Tobiume K., Kishida S.,
RA   Ninomiya-Tsuji J., Matsumoto K., Ichijo H.;
RT   "Involvement of ASK1 in Ca2+-induced p38 MAP kinase activation.";
RL   EMBO Rep. 5:161-166(2004).
RN   [19]
RP   FUNCTION, HOMODIMERIZATION, ENZYME REGULATION, AND PHOSPHORYLATION AT
RP   THR-838.
RX   PubMed=11920685; DOI=10.1002/jcp.10080;
RA   Tobiume K., Saitoh M., Ichijo H.;
RT   "Activation of apoptosis signal-regulating kinase 1 by the stress-
RT   induced activating phosphorylation of pre-formed oligomer.";
RL   J. Cell. Physiol. 191:95-104(2002).
RN   [20]
RP   INTERACTION WITH IGF1R, PHOSPHORYLATION, ENZYME REGULATION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=12556535; DOI=10.1074/jbc.M211398200;
RA   Galvan V., Logvinova A., Sperandio S., Ichijo H., Bredesen D.E.;
RT   "Type 1 insulin-like growth factor receptor (IGF-IR) signaling
RT   inhibits apoptosis signal-regulating kinase 1 (ASK1).";
RL   J. Biol. Chem. 278:13325-13332(2003).
RN   [21]
RP   PHOSPHORYLATION AT SER-83, ENZYME REGULATION, AND FUNCTION.
RX   PubMed=12697749; DOI=10.1074/jbc.M302674200;
RA   Yuan Z.Q., Feldman R.I., Sussman G.E., Coppola D., Nicosia S.V.,
RA   Cheng J.Q.;
RT   "AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by
RT   phosphorylation of ASK1: implication of AKT2 in chemoresistance.";
RL   J. Biol. Chem. 278:23432-23440(2003).
RN   [22]
RP   INTERACTION WITH DAB2IP.
RX   PubMed=12813029; DOI=10.1172/JCI200317790;
RA   Zhang R., He X., Liu W., Lu M., Hsieh J.-T., Min W.;
RT   "AIP1 mediates TNF-alpha-induced ASK1 activation by facilitating
RT   dissociation of ASK1 from its inhibitor 14-3-3.";
RL   J. Clin. Invest. 111:1933-1943(2003).
RN   [23]
RP   INTERACTION WITH YWHAB; YWHAE; YWHAH; YWHAQ; YWHAZ AND SFN, FUNCTION,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=15023544; DOI=10.1016/j.yexcr.2003.12.009;
RA   Subramanian R.R., Zhang H., Wang H., Ichijo H., Miyashita T., Fu H.;
RT   "Interaction of apoptosis signal-regulating kinase 1 with isoforms of
RT   14-3-3 proteins.";
RL   Exp. Cell Res. 294:581-591(2004).
RN   [24]
RP   PHOSPHORYLATION AT SER-966, ENZYME REGULATION, AND FUNCTION.
RX   PubMed=14688258; DOI=10.1074/jbc.M311129200;
RA   Goldman E.H., Chen L., Fu H.;
RT   "Activation of apoptosis signal-regulating kinase 1 by reactive oxygen
RT   species through dephosphorylation at serine 967 and 14-3-3
RT   dissociation.";
RL   J. Biol. Chem. 279:10442-10449(2004).
RN   [25]
RP   INTERACTION WITH DAB2IP.
RX   PubMed=15310755; DOI=10.1074/jbc.M407617200;
RA   Zhang H., Zhang R., Luo Y., D'Alessio A., Pober J.S., Min W.;
RT   "AIP1/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2-
RT   induced ASK1-JNK activation.";
RL   J. Biol. Chem. 279:44955-44965(2004).
RN   [26]
RP   ENZYME REGULATION, PHOSPHORYLATION AT SER-966 AND SER-1033,
RP   MUTAGENESIS OF SER-966 AND SER-1033, AND INTERACTION WITH YWHAG.
RX   PubMed=15094778; DOI=10.1038/sj.onc.1207668;
RA   Fujii K., Goldman E.H., Park H.R., Zhang L., Chen J., Fu H.;
RT   "Negative control of apoptosis signal-regulating kinase 1 through
RT   phosphorylation of Ser-1034.";
RL   Oncogene 23:5099-5104(2004).
RN   [27]
RP   INTERACTION WITH STUB1, AND UBIQUITINATION.
RX   PubMed=16038411; DOI=10.1379/CSC-90R.1;
RA   Hwang J.R., Zhang C., Patterson C.;
RT   "C-terminus of heat shock protein 70-interacting protein facilitates
RT   degradation of apoptosis signal-regulating kinase 1 and inhibits
RT   apoptosis signal-regulating kinase 1-dependent apoptosis.";
RL   Cell Stress Chaperones 10:147-156(2005).
RN   [28]
RP   INTERACTION WITH HIPK1, AND SUBCELLULAR LOCATION.
RX   PubMed=15701637; DOI=10.1074/jbc.M414262200;
RA   Li X., Zhang R., Luo D., Park S.-J., Wang Q., Kim Y., Min W.;
RT   "Tumor necrosis factor alpha-induced desumoylation and cytoplasmic
RT   translocation of homeodomain-interacting protein kinase 1 are critical
RT   for apoptosis signal-regulating kinase 1-JNK/p38 activation.";
RL   J. Biol. Chem. 280:15061-15070(2005).
RN   [29]
RP   SUBUNIT, INTERACTION WITH TRAF2, AND FUNCTION.
RX   PubMed=16129676; DOI=10.1074/jbc.M506771200;
RA   Noguchi T., Takeda K., Matsuzawa A., Saegusa K., Nakano H., Gohda J.,
RA   Inoue J., Ichijo H.;
RT   "Recruitment of tumor necrosis factor receptor-associated factor
RT   family proteins to apoptosis signal-regulating kinase 1 signalosome is
RT   essential for oxidative stress-induced cell death.";
RL   J. Biol. Chem. 280:37033-37040(2005).
RN   [30]
RP   PHOSPHORYLATION AT TYR-718, INTERACTION WITH SOCS1, AND ENZYME
RP   REGULATION.
RX   PubMed=16407264; DOI=10.1074/jbc.M512338200;
RA   He Y., Zhang W., Zhang R., Zhang H., Min W.;
RT   "SOCS1 inhibits tumor necrosis factor-induced activation of ASK1-JNK
RT   inflammatory signaling by mediating ASK1 degradation.";
RL   J. Biol. Chem. 281:5559-5566(2006).
RN   [31]
RP   INTERACTION WITH PPM1L.
RX   PubMed=17456047; DOI=10.1042/BJ20070231;
RA   Saito J., Toriumi S., Awano K., Ichijo H., Sasaki K., Kobayashi T.,
RA   Tamura S.;
RT   "Regulation of apoptosis signal-regulating kinase 1 by protein
RT   phosphatase 2Cepsilon.";
RL   Biochem. J. 405:591-596(2007).
RN   [32]
RP   ENZYME REGULATION, INTERACTION WITH MAP3K5, PHOSPHORYLATION AT
RP   THR-838, AND MUTAGENESIS OF LYS-709.
RX   PubMed=17210579; DOI=10.1074/jbc.M607177200;
RA   Takeda K., Shimozono R., Noguchi T., Umeda T., Morimoto Y., Naguro I.,
RA   Tobiume K., Saitoh M., Matsuzawa A., Ichijo H.;
RT   "Apoptosis signal-regulating kinase (ASK) 2 functions as a mitogen-
RT   activated protein kinase kinase kinase in a heteromeric complex with
RT   ASK1.";
RL   J. Biol. Chem. 282:7522-7531(2007).
RN   [33]
RP   INTERACTION WITH BIRC2, UBIQUITINATION, AND FUNCTION.
RX   PubMed=17220297; DOI=10.1074/jbc.M609146200;
RA   Zhao Y., Conze D.B., Hanover J.A., Ashwell J.D.;
RT   "Tumor necrosis factor receptor 2 signaling induces selective c-IAP1-
RT   dependent ASK1 ubiquitination and terminates mitogen-activated protein
RT   kinase signaling.";
RL   J. Biol. Chem. 282:7777-7782(2007).
RN   [34]
RP   INTERACTION WITH DAB2IP.
RX   PubMed=17389591; DOI=10.1074/jbc.M701148200;
RA   Zhang H., Zhang H., Lin Y., Li J., Pober J.S., Min W.;
RT   "RIP1-mediated AIP1 phosphorylation at a 14-3-3-binding site is
RT   critical for tumor necrosis factor-induced ASK1-JNK/p38 activation.";
RL   J. Biol. Chem. 282:14788-14796(2007).
RN   [35]
RP   INTERACTION WITH TRAF2; TRAF6 AND TXN.
RX   PubMed=17724081; DOI=10.1128/MCB.00227-07;
RA   Fujino G., Noguchi T., Matsuzawa A., Yamauchi S., Saitoh M.,
RA   Takeda K., Ichijo H.;
RT   "Thioredoxin and TRAF family proteins regulate reactive oxygen
RT   species-dependent activation of ASK1 through reciprocal modulation of
RT   the N-terminal homophilic interaction of ASK1.";
RL   Mol. Cell. Biol. 27:8152-8163(2007).
RN   [36]
RP   INTERACTION WITH ARRB2.
RX   PubMed=18408005; DOI=10.1074/jbc.M710006200;
RA   Guo C., Whitmarsh A.J.;
RT   "The beta-arrestin-2 scaffold protein promotes c-Jun N-terminal
RT   kinase-3 activation by binding to its nonconserved N terminus.";
RL   J. Biol. Chem. 283:15903-15911(2008).
RN   [37]
RP   PHOSPHORYLATION AT THR-838.
RX   PubMed=18948261; DOI=10.1074/jbc.M807219200;
RA   Jung H., Seong H.A., Ha H.;
RT   "Murine protein serine/threonine kinase 38 activates apoptosis signal-
RT   regulating kinase 1 via Thr 838 phosphorylation.";
RL   J. Biol. Chem. 283:34541-34553(2008).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1029 AND SER-1033, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1029 AND SER-1033, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1033, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [41]
RP   PHOSPHORYLATION AT SER-83 BY PIM1, AND INTERACTION WITH PIM1.
RX   PubMed=19749799; DOI=10.1038/onc.2009.276;
RA   Gu J.J., Wang Z., Reeves R., Magnuson N.S.;
RT   "PIM1 phosphorylates and negatively regulates ASK1-mediated
RT   apoptosis.";
RL   Oncogene 28:4261-4271(2009).
RN   [42]
RP   INTERACTION WITH PGAM5, AND PHOSPHORYLATION AT THR-838; SER-966 AND
RP   SER-1033.
RX   PubMed=19590015; DOI=10.1073/pnas.0901823106;
RA   Takeda K., Komuro Y., Hayakawa T., Oguchi H., Ishida Y., Murakami S.,
RA   Noguchi T., Kinoshita H., Sekine Y., Iemura S., Natsume T., Ichijo H.;
RT   "Mitochondrial phosphoglycerate mutase 5 uses alternate catalytic
RT   activity as a protein serine/threonine phosphatase to activate ASK1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:12301-12305(2009).
RN   [43]
RP   REVIEW ON ENZYME REGULATION, AND REVIEW ON FUNCTION.
RX   PubMed=17883330; DOI=10.1146/annurev.pharmtox.48.113006.094606;
RA   Takeda K., Noguchi T., Naguro I., Ichijo H.;
RT   "Apoptosis signal-regulating kinase 1 in stress and immune response.";
RL   Annu. Rev. Pharmacol. Toxicol. 48:199-225(2008).
RN   [44]
RP   REVIEW ON ENZYME REGULATION, AND REVIEW ON FUNCTION.
RX   PubMed=19389260; DOI=10.1186/1478-811X-7-9;
RA   Hattori K., Naguro I., Runchel C., Ichijo H.;
RT   "The roles of ASK family proteins in stress responses and diseases.";
RL   Cell Commun. Signal. 7:9-9(2009).
RN   [45]
RP   INTERACTION WITH DUSP13.
RX   PubMed=20358250; DOI=10.1007/s00018-010-0353-3;
RA   Park J.E., Park B.C., Kim H.A., Song M., Park S.G., Lee D.H.,
RA   Kim H.J., Choi H.K., Kim J.T., Cho S.;
RT   "Positive regulation of apoptosis signal-regulating kinase 1 by dual-
RT   specificity phosphatase 13A.";
RL   Cell. Mol. Life Sci. 67:2619-2629(2010).
RN   [46]
RP   FUNCTION, PHOSPHORYLATION AT THR-838, AND DEPHOSPHORYLATION AT THR-838
RP   BY PPP5C.
RX   PubMed=23102700; DOI=10.1016/j.molcel.2012.09.018;
RA   Sekine Y., Hatanaka R., Watanabe T., Sono N., Iemura S., Natsume T.,
RA   Kuranaga E., Miura M., Takeda K., Ichijo H.;
RT   "The Kelch repeat protein KLHDC10 regulates oxidative stress-induced
RT   ASK1 activation by suppressing PP5.";
RL   Mol. Cell 48:692-704(2012).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-958, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [48]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [49]
RP   INTERACTION WITH RC3H2, AND MUTAGENESIS OF LYS-709.
RX   PubMed=24448648; DOI=10.1126/scisignal.2004822;
RA   Maruyama T., Araki T., Kawarazaki Y., Naguro I., Heynen S.,
RA   Aza-Blanc P., Ronai Z., Matsuzawa A., Ichijo H.;
RT   "Roquin-2 promotes ubiquitin-mediated degradation of ASK1 to regulate
RT   stress responses.";
RL   Sci. Signal. 7:RA8-RA8(2014).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 659-951, AND PHOSPHORYLATION
RP   AT THR-813; THR-838 AND THR-842.
RX   PubMed=17937911; DOI=10.1016/j.str.2007.08.011;
RA   Bunkoczi G., Salah E., Filippakopoulos P., Fedorov O., Muller S.,
RA   Sobott F., Parker S.A., Zhang H., Min W., Turk B.E., Knapp S.;
RT   "Structural and functional characterization of the human protein
RT   kinase ASK1.";
RL   Structure 15:1215-1226(2007).
RN   [51]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-1006; THR-1214; VAL-1250; ILE-1314
RP   AND ASN-1315.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine kinase which acts as an essential
CC       component of the MAP kinase signal transduction pathway. Plays an
CC       important role in the cascades of cellular responses evoked by
CC       changes in the environment. Mediates signaling for determination
CC       of cell fate such as differentiation and survival. Plays a crucial
CC       role in the apoptosis signal transduction pathway through
CC       mitochondria-dependent caspase activation. MAP3K5/ASK1 is required
CC       for the innate immune response, which is essential for host
CC       defense against a wide range of pathogens. Mediates signal
CC       transduction of various stressors like oxidative stress as well as
CC       by receptor-mediated inflammatory signals, such as the tumor
CC       necrosis factor (TNF) or lipopolysaccharide (LPS). Once activated,
CC       acts as an upstream activator of the MKK/JNK signal transduction
CC       cascade and the p38 MAPK signal transduction cascade through the
CC       phosphorylation and activation of several MAP kinase kinases like
CC       MAP2K4/SEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7. These
CC       MAP2Ks in turn activate p38 MAPKs and c-jun N-terminal kinases
CC       (JNKs). Both p38 MAPK and JNKs control the transcription factors
CC       activator protein-1 (AP-1). {ECO:0000269|PubMed:10411906,
CC       ECO:0000269|PubMed:10688666, ECO:0000269|PubMed:10849426,
CC       ECO:0000269|PubMed:11029458, ECO:0000269|PubMed:11154276,
CC       ECO:0000269|PubMed:11689443, ECO:0000269|PubMed:11920685,
CC       ECO:0000269|PubMed:12697749, ECO:0000269|PubMed:14688258,
CC       ECO:0000269|PubMed:14749717, ECO:0000269|PubMed:15023544,
CC       ECO:0000269|PubMed:16129676, ECO:0000269|PubMed:17220297,
CC       ECO:0000269|PubMed:23102700, ECO:0000269|PubMed:8940179,
CC       ECO:0000269|PubMed:8974401, ECO:0000269|PubMed:9564042,
CC       ECO:0000269|PubMed:9774977}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Activated by various stressors, including
CC       oxidative stress, endoplasmic reticulum stress, and calcium
CC       overload, as well as by receptor-mediated inflammatory signals,
CC       such as the tumor necrosis factor (TNF) and lipopolysaccharide
CC       (LPS). Homophilic association of MAP3K5/ASK1 through the C-
CC       terminal coiled-coil domains and the heteromeric complex formation
CC       of MAP3K5/ASK1 with the reduced form of thioredoxin (TXN),
CC       constitutes an inactive form of the kinase (PubMed:17210579,
CC       PubMed:9564042). Upon ROS-induced dissociation of TXN from
CC       MAP3K5/ASK1, TRAF2 and TRAF6 are reciprocally recruited to
CC       MAP3K5/ASK1 and form the active MAP3K5/ASK1 signalosome, in which
CC       TRAF2 and TRAF6 appear to facilitate the active configuration of
CC       MAP3K5/ASK1 (PubMed:9774977, PubMed:10688666, PubMed:11920685).
CC       MAP3K5/ASK1 activity is also regulated through several
CC       phosphorylation and dephosphorylation events. Thr-838 is an
CC       activating phosphorylation site that is autophosphorylated and
CC       phosphorylated by MAP3K6/ASK2 and dephosphorylated by PPP5C
CC       (PubMed:11689443). Ser-83 and Ser-1033 are inactivating
CC       phosphorylation sites, the former of which is phosphorylated by
CC       AKT1 and AKT2 (PubMed:11154276, PubMed:12697749, PubMed:15094778).
CC       Phosphorylation of Ser-966 induces association of MAP3K5/ASK1 with
CC       the 14-3-3 family proteins, which suppresses MAP3K5/ASK1 activity
CC       (PubMed:10411906, PubMed:14688258). Calcium/calmodulin-activated
CC       protein phosphatase calcineurin (PPP3CA) has been shown to
CC       directly dephosphorylate this site (PubMed:14749717). SOCS1 binds
CC       to ASK1 by recognizing phosphorylation of Tyr-718 and induces
CC       MAP3K5/ASK1 degradation in endothelial cells (PubMed:16407264).
CC       Also dephosphorylated and activated by PGAM5. Contains an N-
CC       terminal autoinhibitory domain. Once activated targeted for
CC       proteosomal degradation by RC3H2-mediated ubiquitination
CC       (PubMed:24448648). {ECO:0000269|PubMed:10411906,
CC       ECO:0000269|PubMed:10688666, ECO:0000269|PubMed:11154276,
CC       ECO:0000269|PubMed:11689443, ECO:0000269|PubMed:11920685,
CC       ECO:0000269|PubMed:12556535, ECO:0000269|PubMed:12697749,
CC       ECO:0000269|PubMed:14688258, ECO:0000269|PubMed:14749717,
CC       ECO:0000269|PubMed:15094778, ECO:0000269|PubMed:16407264,
CC       ECO:0000269|PubMed:17210579, ECO:0000269|PubMed:24448648,
CC       ECO:0000269|PubMed:9564042, ECO:0000269|PubMed:9774977}.
CC   -!- SUBUNIT: Homodimer when inactive. Binds both upstream activators
CC       and downstream substrates in multimolecular complexes. Associates
CC       with and inhibited by HIV-1 Nef (PubMed:11298454). Part of a
CC       cytoplasmic complex made of HIPK1, DAB2IP and MAP3K5 in response
CC       to TNF (PubMed:15310755, PubMed:15701637, PubMed:17210579,
CC       PubMed:17389591). This complex formation promotes MAP3K5-JNK
CC       activation and subsequent apoptosis. Interacts with SOCS1 which
CC       recognizes phosphorylation of Tyr-718 and induces MAP3K5/ASK1
CC       degradation in endothelial cells. Interacts with the 14-3-3 family
CC       proteins such as YWHAB, YWHAE, YWHAQ, YWHAH, YWHAZ and SFN
CC       (PubMed:10411906, PubMed:15023544, PubMed:15094778). Interacts
CC       with ARRB2, BIRC2, DAB2IP, IGF1R, MAP3K6/ASK2, PGAM5, PIM1, PPP5C,
CC       SOCS1, STUB1, TRAF2, TRAF6 and TXN (PubMed:9564042,PubMed:9774977,
CC       PubMed:10688666, PubMed:11090355, PubMed:11689443,
CC       PubMed:12556535, PubMed:12813029, PubMed:15310755,
CC       PubMed:16038411, PubMed:16129676, PubMed:16407264,
CC       PubMed:17220297, PubMed:17724081, PubMed:18408005,
CC       PubMed:19590015, PubMed:19749799). Interacts with ERN1 in a TRAF2-
CC       dependent manner (PubMed:14749717). Interacts with calcineurin
CC       subunit PPP3R1 and with PPM1L (PubMed:17456047) (By similarity).
CC       Interacts (via N-terminus) with RAF1 and this interaction inhibits
CC       the proapoptotic function of MAP3K5 (PubMed:11427728). Interacts
CC       with DAB2IP (via N-terminus C2 domain); the interaction occurs in
CC       a TNF-alpha-dependent manner (PubMed:15310755). Interacts with
CC       DUSP13/DUSP13A; may positively regulate apoptosis
CC       (PubMed:20358250). Interacts with DAXX (PubMed:9743501). Interacts
CC       with RC3H2 (PubMed:24448648). {ECO:0000250,
CC       ECO:0000269|PubMed:10411906, ECO:0000269|PubMed:10688666,
CC       ECO:0000269|PubMed:11090355, ECO:0000269|PubMed:11298454,
CC       ECO:0000269|PubMed:11427728, ECO:0000269|PubMed:11689443,
CC       ECO:0000269|PubMed:12556535, ECO:0000269|PubMed:12813029,
CC       ECO:0000269|PubMed:14749717, ECO:0000269|PubMed:15023544,
CC       ECO:0000269|PubMed:15094778, ECO:0000269|PubMed:15310755,
CC       ECO:0000269|PubMed:15701637, ECO:0000269|PubMed:16038411,
CC       ECO:0000269|PubMed:16129676, ECO:0000269|PubMed:16407264,
CC       ECO:0000269|PubMed:17210579, ECO:0000269|PubMed:17220297,
CC       ECO:0000269|PubMed:17389591, ECO:0000269|PubMed:17456047,
CC       ECO:0000269|PubMed:17724081, ECO:0000269|PubMed:18408005,
CC       ECO:0000269|PubMed:19590015, ECO:0000269|PubMed:19749799,
CC       ECO:0000269|PubMed:20358250, ECO:0000269|PubMed:24448648,
CC       ECO:0000269|PubMed:9564042, ECO:0000269|PubMed:9743501,
CC       ECO:0000269|PubMed:9774977}.
CC   -!- INTERACTION:
CC       P31749:AKT1; NbExp=2; IntAct=EBI-476263, EBI-296087;
CC       P05067:APP; NbExp=2; IntAct=EBI-476263, EBI-77613;
CC       P49407:ARRB1; NbExp=3; IntAct=EBI-476263, EBI-743313;
CC       P32121:ARRB2; NbExp=2; IntAct=EBI-476263, EBI-714559;
CC       Q5VWQ8:DAB2IP; NbExp=2; IntAct=EBI-476263, EBI-2871881;
CC       Q9UER7:DAXX; NbExp=7; IntAct=EBI-476263, EBI-77321;
CC       P25445:FAS; NbExp=2; IntAct=EBI-476263, EBI-494743;
CC       P46734:MAP2K3; NbExp=2; IntAct=EBI-476263, EBI-602462;
CC       Q9WTR2:Map3k6 (xeno); NbExp=3; IntAct=EBI-476263, EBI-1254790;
CC       Q96EZ8:MCRS1; NbExp=3; IntAct=EBI-476263, EBI-348259;
CC       P63098:PPP3R1; NbExp=2; IntAct=EBI-476263, EBI-915984;
CC       Q16637:SMN2; NbExp=3; IntAct=EBI-476263, EBI-395421;
CC       P10599:TXN; NbExp=2; IntAct=EBI-476263, EBI-594644;
CC       P31946:YWHAB; NbExp=3; IntAct=EBI-476263, EBI-359815;
CC       P63104:YWHAZ; NbExp=4; IntAct=EBI-476263, EBI-347088;
CC       Q969S3:ZNF622; NbExp=14; IntAct=EBI-476263, EBI-2687480;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Endoplasmic reticulum.
CC       Note=Interaction with 14-3-3 proteins alters the distribution of
CC       MAP3K5/ASK1 and restricts it to the perinuclear endoplasmic
CC       reticulum region.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q99683-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q99683-2; Sequence=VSP_056182;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Abundantly expressed in heart and pancreas.
CC   -!- INDUCTION: By TNF. Inhibited by HIV-1 Nef.
CC   -!- PTM: Phosphorylated at Thr-838 through autophosphorylation and by
CC       MAP3K6/ASK2 which leads to activation. Thr-838 is dephosphorylated
CC       by PPP5C. Ser-83 and Ser-1033 are inactivating phosphorylation
CC       sites, the former of which is phosphorylated by AKT1 and AKT2.
CC       Phosphorylated at Ser-966 which induces association of MAP3K5/ASK1
CC       with the 14-3-3 family proteins and suppresses MAP3K5/ASK1
CC       activity. Calcineurin (CN) dephosphorylates this site. Also
CC       dephosphorylated and activated by PGAM5.
CC       {ECO:0000269|PubMed:11154276, ECO:0000269|PubMed:11920685,
CC       ECO:0000269|PubMed:12556535, ECO:0000269|PubMed:12697749,
CC       ECO:0000269|PubMed:14688258, ECO:0000269|PubMed:15094778,
CC       ECO:0000269|PubMed:16407264, ECO:0000269|PubMed:17210579,
CC       ECO:0000269|PubMed:17937911, ECO:0000269|PubMed:18948261,
CC       ECO:0000269|PubMed:19590015, ECO:0000269|PubMed:19749799,
CC       ECO:0000269|PubMed:23102700}.
CC   -!- PTM: Ubiquitinated. Tumor necrosis factor (TNF) induces TNFR2-
CC       dependent ubiquitination leading to proteasomal degradation.
CC       {ECO:0000269|PubMed:16038411, ECO:0000269|PubMed:17220297}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase kinase subfamily.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U67156; AAC50894.1; -; mRNA.
DR   EMBL; D84476; BAA12684.2; -; mRNA.
DR   EMBL; AK294507; BAG57723.1; -; mRNA.
DR   EMBL; AL024508; CAI20176.1; -; Genomic_DNA.
DR   EMBL; AL121933; CAI20176.1; JOINED; Genomic_DNA.
DR   EMBL; AL121933; CAI15470.1; -; Genomic_DNA.
DR   EMBL; AL024508; CAI15470.1; JOINED; Genomic_DNA.
DR   EMBL; BC054503; AAH54503.1; -; mRNA.
DR   EMBL; BC088829; AAH88829.1; -; mRNA.
DR   CCDS; CCDS5179.1; -. [Q99683-1]
DR   RefSeq; NP_005914.1; NM_005923.3. [Q99683-1]
DR   UniGene; Hs.186486; -.
DR   PDB; 2CLQ; X-ray; 2.30 A; A/B=659-951.
DR   PDB; 3VW6; X-ray; 2.40 A; A/B=671-939.
DR   PDB; 4BF2; X-ray; 2.11 A; A/B=660-977.
DR   PDB; 4BHN; X-ray; 2.30 A; A/B=660-977.
DR   PDB; 4BIB; X-ray; 2.43 A; A/B=660-977.
DR   PDB; 4BIC; X-ray; 2.62 A; A/B=660-977.
DR   PDB; 4BID; X-ray; 2.80 A; A/B=660-977.
DR   PDB; 4BIE; X-ray; 2.36 A; A/B=660-977.
DR   PDB; 5ULM; X-ray; 2.10 A; A/B=269-658.
DR   PDB; 5V19; X-ray; 3.10 A; A/B=670-940.
DR   PDB; 5V24; X-ray; 2.50 A; A/B=670-940.
DR   PDBsum; 2CLQ; -.
DR   PDBsum; 3VW6; -.
DR   PDBsum; 4BF2; -.
DR   PDBsum; 4BHN; -.
DR   PDBsum; 4BIB; -.
DR   PDBsum; 4BIC; -.
DR   PDBsum; 4BID; -.
DR   PDBsum; 4BIE; -.
DR   PDBsum; 5ULM; -.
DR   PDBsum; 5V19; -.
DR   PDBsum; 5V24; -.
DR   ProteinModelPortal; Q99683; -.
DR   SMR; Q99683; -.
DR   BioGrid; 110381; 83.
DR   DIP; DIP-29516N; -.
DR   IntAct; Q99683; 42.
DR   MINT; MINT-99796; -.
DR   STRING; 9606.ENSP00000351908; -.
DR   BindingDB; Q99683; -.
DR   ChEMBL; CHEMBL5285; -.
DR   GuidetoPHARMACOLOGY; 2080; -.
DR   iPTMnet; Q99683; -.
DR   PhosphoSitePlus; Q99683; -.
DR   BioMuta; MAP3K5; -.
DR   DMDM; 6685617; -.
DR   EPD; Q99683; -.
DR   MaxQB; Q99683; -.
DR   PaxDb; Q99683; -.
DR   PeptideAtlas; Q99683; -.
DR   PRIDE; Q99683; -.
DR   DNASU; 4217; -.
DR   Ensembl; ENST00000359015; ENSP00000351908; ENSG00000197442. [Q99683-1]
DR   GeneID; 4217; -.
DR   KEGG; hsa:4217; -.
DR   UCSC; uc003qhc.4; human. [Q99683-1]
DR   CTD; 4217; -.
DR   DisGeNET; 4217; -.
DR   GeneCards; MAP3K5; -.
DR   HGNC; HGNC:6857; MAP3K5.
DR   HPA; CAB007824; -.
DR   HPA; HPA063245; -.
DR   HPA; HPA064423; -.
DR   MIM; 602448; gene.
DR   neXtProt; NX_Q99683; -.
DR   OpenTargets; ENSG00000197442; -.
DR   PharmGKB; PA30601; -.
DR   eggNOG; KOG4279; Eukaryota.
DR   eggNOG; ENOG410XQGS; LUCA.
DR   GeneTree; ENSGT00800000124036; -.
DR   HOGENOM; HOG000293286; -.
DR   HOVERGEN; HBG006305; -.
DR   InParanoid; Q99683; -.
DR   KO; K04426; -.
DR   OMA; TELHCKK; -.
DR   OrthoDB; EOG091G00SJ; -.
DR   PhylomeDB; Q99683; -.
DR   TreeFam; TF105115; -.
DR   BRENDA; 2.7.12.2; 2681.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   SignaLink; Q99683; -.
DR   SIGNOR; Q99683; -.
DR   ChiTaRS; MAP3K5; human.
DR   EvolutionaryTrace; Q99683; -.
DR   GeneWiki; ASK1; -.
DR   GenomeRNAi; 4217; -.
DR   PRO; PR:Q99683; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000197442; -.
DR   CleanEx; HS_MAP3K5; -.
DR   Genevisible; Q99683; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:1990604; C:IRE1-TRAF2-ASK1 complex; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0043234; C:protein complex; IMP:CAFA.
DR   GO; GO:1902911; C:protein kinase complex; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0004709; F:MAP kinase kinase kinase activity; IDA:UniProtKB.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:CAFA.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome.
DR   GO; GO:0007257; P:activation of JUN kinase activity; TAS:ProtInc.
DR   GO; GO:0000186; P:activation of MAPKK activity; IDA:BHF-UCL.
DR   GO; GO:0097190; P:apoptotic signaling pathway; TAS:ProtInc.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; IDA:CAFA.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IDA:BHF-UCL.
DR   GO; GO:1902170; P:cellular response to reactive nitrogen species; IEA:Ensembl.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0072577; P:endothelial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0008631; P:intrinsic apoptotic signaling pathway in response to oxidative stress; IDA:UniProtKB.
DR   GO; GO:0007254; P:JNK cascade; IDA:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0038066; P:p38MAPK cascade; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:BHF-UCL.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0045663; P:positive regulation of myoblast differentiation; IEA:Ensembl.
DR   GO; GO:1901216; P:positive regulation of neuron death; IGI:ParkinsonsUK-UCL.
DR   GO; GO:1900745; P:positive regulation of p38MAPK cascade; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:CAFA.
DR   GO; GO:1904707; P:positive regulation of vascular smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0097300; P:programmed necrotic cell death; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:CAFA.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0002931; P:response to ischemia; IEA:Ensembl.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; IDA:CAFA.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   InterPro; IPR025136; DUF4071.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR013761; SAM/pointed.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF13281; DUF4071; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding;
KW   Coiled coil; Complete proteome; Cytoplasm; Endoplasmic reticulum;
KW   Host-virus interaction; Immunity; Innate immunity; Kinase; Magnesium;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Stress response;
KW   Transferase; Ubl conjugation.
FT   CHAIN         1   1374       Mitogen-activated protein kinase kinase
FT                                kinase 5.
FT                                /FTId=PRO_0000086249.
FT   DOMAIN      680    938       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     686    694       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COILED     1245   1285       {ECO:0000255}.
FT   ACT_SITE    803    803       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     709    709       ATP.
FT   MOD_RES      83     83       Phosphoserine; by PIM1, PKB/AKT1 and
FT                                PKB/AKT2. {ECO:0000269|PubMed:11154276,
FT                                ECO:0000269|PubMed:12697749,
FT                                ECO:0000269|PubMed:19749799}.
FT   MOD_RES     718    718       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:16407264}.
FT   MOD_RES     813    813       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:17937911}.
FT   MOD_RES     838    838       Phosphothreonine; by autocatalysis, MELK
FT                                and MAP3K6. {ECO:0000269|PubMed:11920685,
FT                                ECO:0000269|PubMed:17210579,
FT                                ECO:0000269|PubMed:17937911,
FT                                ECO:0000269|PubMed:18948261,
FT                                ECO:0000269|PubMed:19590015,
FT                                ECO:0000269|PubMed:23102700}.
FT   MOD_RES     842    842       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:17937911}.
FT   MOD_RES     958    958       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     966    966       Phosphoserine.
FT                                {ECO:0000269|PubMed:14688258,
FT                                ECO:0000269|PubMed:15094778,
FT                                ECO:0000269|PubMed:19590015}.
FT   MOD_RES    1029   1029       Phosphoserine.
FT                                {ECO:0000244|PubMed:18088087,
FT                                ECO:0000244|PubMed:18669648}.
FT   MOD_RES    1033   1033       Phosphoserine.
FT                                {ECO:0000244|PubMed:18088087,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:15094778,
FT                                ECO:0000269|PubMed:19590015}.
FT   VAR_SEQ       1    753       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056182.
FT   VARIANT    1006   1006       G -> R (in dbSNP:rs45626535).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040693.
FT   VARIANT    1214   1214       I -> T (in dbSNP:rs56379668).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040694.
FT   VARIANT    1250   1250       I -> V (in dbSNP:rs35551087).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040695.
FT   VARIANT    1314   1314       T -> I (in dbSNP:rs45599539).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040696.
FT   VARIANT    1315   1315       D -> N (in dbSNP:rs41288957).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040697.
FT   MUTAGEN     709    709       K->M: Loss of kinase activity. Inhibits
FT                                activation of JNK and apoptosis mediated
FT                                by TNFRSF6 and DAXX.
FT                                {ECO:0000269|PubMed:17210579,
FT                                ECO:0000269|PubMed:9743501}.
FT   MUTAGEN     709    709       K->R: Loss of kinase activity. Abolishes
FT                                DAXX-mediated apoptosis. Loss of RC3H2-
FT                                mediated ubiquitination.
FT                                {ECO:0000269|PubMed:17210579,
FT                                ECO:0000269|PubMed:24448648,
FT                                ECO:0000269|PubMed:9743501}.
FT   MUTAGEN     966    966       S->A: Enhanced induction of apoptosis,
FT                                increased kinase activity, and loss of
FT                                YWHAG binding.
FT                                {ECO:0000269|PubMed:10411906,
FT                                ECO:0000269|PubMed:15094778}.
FT   MUTAGEN    1033   1033       S->A: Enhanced induction of apoptosis and
FT                                increased kinase activity.
FT                                {ECO:0000269|PubMed:15094778}.
FT   HELIX       273    286       {ECO:0000244|PDB:5ULM}.
FT   HELIX       289    303       {ECO:0000244|PDB:5ULM}.
FT   HELIX       311    323       {ECO:0000244|PDB:5ULM}.
FT   HELIX       327    339       {ECO:0000244|PDB:5ULM}.
FT   HELIX       345    347       {ECO:0000244|PDB:5ULM}.
FT   HELIX       349    362       {ECO:0000244|PDB:5ULM}.
FT   HELIX       367    379       {ECO:0000244|PDB:5ULM}.
FT   HELIX       387    403       {ECO:0000244|PDB:5ULM}.
FT   TURN        404    406       {ECO:0000244|PDB:5ULM}.
FT   HELIX       409    425       {ECO:0000244|PDB:5ULM}.
FT   HELIX       429    441       {ECO:0000244|PDB:5ULM}.
FT   HELIX       452    466       {ECO:0000244|PDB:5ULM}.
FT   HELIX       469    471       {ECO:0000244|PDB:5ULM}.
FT   HELIX       475    487       {ECO:0000244|PDB:5ULM}.
FT   HELIX       491    503       {ECO:0000244|PDB:5ULM}.
FT   HELIX       508    524       {ECO:0000244|PDB:5ULM}.
FT   HELIX       536    548       {ECO:0000244|PDB:5ULM}.
FT   STRAND      557    564       {ECO:0000244|PDB:5ULM}.
FT   STRAND      570    578       {ECO:0000244|PDB:5ULM}.
FT   STRAND      581    583       {ECO:0000244|PDB:5ULM}.
FT   STRAND      585    592       {ECO:0000244|PDB:5ULM}.
FT   STRAND      601    605       {ECO:0000244|PDB:5ULM}.
FT   HELIX       606    608       {ECO:0000244|PDB:5ULM}.
FT   STRAND      609    614       {ECO:0000244|PDB:5ULM}.
FT   STRAND      621    626       {ECO:0000244|PDB:5ULM}.
FT   STRAND      633    636       {ECO:0000244|PDB:5ULM}.
FT   HELIX       640    654       {ECO:0000244|PDB:5ULM}.
FT   STRAND      673    675       {ECO:0000244|PDB:4BF2}.
FT   STRAND      681    683       {ECO:0000244|PDB:2CLQ}.
FT   STRAND      685    688       {ECO:0000244|PDB:4BF2}.
FT   STRAND      693    699       {ECO:0000244|PDB:4BF2}.
FT   TURN        700    702       {ECO:0000244|PDB:4BF2}.
FT   STRAND      705    712       {ECO:0000244|PDB:4BF2}.
FT   HELIX       725    729       {ECO:0000244|PDB:4BF2}.
FT   STRAND      740    746       {ECO:0000244|PDB:4BF2}.
FT   STRAND      749    755       {ECO:0000244|PDB:4BF2}.
FT   STRAND      758    761       {ECO:0000244|PDB:4BF2}.
FT   HELIX       762    768       {ECO:0000244|PDB:4BF2}.
FT   HELIX       777    796       {ECO:0000244|PDB:4BF2}.
FT   HELIX       806    808       {ECO:0000244|PDB:4BF2}.
FT   STRAND      809    812       {ECO:0000244|PDB:4BF2}.
FT   TURN        813    815       {ECO:0000244|PDB:4BF2}.
FT   STRAND      818    820       {ECO:0000244|PDB:4BF2}.
FT   TURN        823    825       {ECO:0000244|PDB:2CLQ}.
FT   STRAND      827    829       {ECO:0000244|PDB:2CLQ}.
FT   HELIX       843    845       {ECO:0000244|PDB:4BF2}.
FT   HELIX       848    853       {ECO:0000244|PDB:4BF2}.
FT   HELIX       854    857       {ECO:0000244|PDB:4BF2}.
FT   HELIX       860    876       {ECO:0000244|PDB:4BF2}.
FT   HELIX       882    884       {ECO:0000244|PDB:4BF2}.
FT   HELIX       887    897       {ECO:0000244|PDB:4BF2}.
FT   HELIX       909    918       {ECO:0000244|PDB:4BF2}.
FT   TURN        923    925       {ECO:0000244|PDB:4BF2}.
FT   HELIX       929    933       {ECO:0000244|PDB:4BF2}.
FT   HELIX       936    938       {ECO:0000244|PDB:4BF2}.
SQ   SEQUENCE   1374 AA;  154537 MW;  265BDC65968AF985 CRC64;
     MSTEADEGIT FSVPPFAPSG FCTIPEGGIC RRGGAAAVGE GEEHQLPPPP PGSFWNVESA
     AAPGIGCPAA TSSSSATRGR GSSVGGGSRR TTVAYVINEA SQGQLVVAES EALQSLREAC
     ETVGATLETL HFGKLDFGET TVLDRFYNAD IAVVEMSDAF RQPSLFYHLG VRESFSMANN
     IILYCDTNSD SLQSLKEIIC QKNTMCTGNY TFVPYMITPH NKVYCCDSSF MKGLTELMQP
     NFELLLGPIC LPLVDRFIQL LKVAQASSSQ YFRESILNDI RKARNLYTGK ELAAELARIR
     QRVDNIEVLT ADIVINLLLS YRDIQDYDSI VKLVETLEKL PTFDLASHHH VKFHYAFALN
     RRNLPGDRAK ALDIMIPMVQ SEGQVASDMY CLVGRIYKDM FLDSNFTDTE SRDHGASWFK
     KAFESEPTLQ SGINYAVLLL AAGHQFESSF ELRKVGVKLS SLLGKKGNLE KLQSYWEVGF
     FLGASVLAND HMRVIQASEK LFKLKTPAWY LKSIVETILI YKHFVKLTTE QPVAKQELVD
     FWMDFLVEAT KTDVTVVRFP VLILEPTKIY QPSYLSINNE VEEKTISIWH VLPDDKKGIH
     EWNFSASSVR GVSISKFEER CCFLYVLHNS DDFQIYFCTE LHCKKFFEMV NTITEEKGRS
     TEEGDCESDL LEYDYEYDEN GDRVVLGKGT YGIVYAGRDL SNQVRIAIKE IPERDSRYSQ
     PLHEEIALHK HLKHKNIVQY LGSFSENGFI KIFMEQVPGG SLSALLRSKW GPLKDNEQTI
     GFYTKQILEG LKYLHDNQIV HRDIKGDNVL INTYSGVLKI SDFGTSKRLA GINPCTETFT
     GTLQYMAPEI IDKGPRGYGK AADIWSLGCT IIEMATGKPP FYELGEPQAA MFKVGMFKVH
     PEIPESMSAE AKAFILKCFE PDPDKRACAN DLLVDEFLKV SSKKKKTQPK LSALSAGSNE
     YLRSISLPVP VLVEDTSSSS EYGSVSPDTE LKVDPFSFKT RAKSCGERDV KGIRTLFLGI
     PDENFEDHSA PPSPEEKDSG FFMLRKDSER RATLHRILTE DQDKIVRNLM ESLAQGAEEP
     KLKWEHITTL IASLREFVRS TDRKIIATTL SKLKLELDFD SHGISQVQVV LFGFQDAVNK
     VLRNHNIKPH WMFALDSIIR KAVQTAITIL VPELRPHFSL ASESDTADQE DLDVEDDHEE
     QPSNQTVRRP QAVIEDAVAT SGVSTLSSTV SHDSQSAHRS LNVQLGRMKI ETNRLLEELV
     RKEKELQALL HRAIEEKDQE IKHLKLKSQP IEIPELPVFH LNSSGTNTED SELTDWLRVN
     GADEDTISRF LAEDYTLLDV LYYVTRDDLK CLRLRGGMLC TLWKAIIDFR NKQT
//
